MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation. This innovation is driven by:
Strong Global Academic and Research Partnerships
GTG’s global academic connections are exemplified by the Company’s collaboration with several high-profile universities involving a range of translational research projects, all focused on delivering a platform for the next generation of risk assessments tests.
Some examples of these projects include but are not limited to:
These research projects highlight GTG’s deep commitment to expand the risk assessment testing space enabling more effective stratification of patients at risk of developing serious disease.
Continuous Enhancement of Current Portfolio
GTG continues to drive enhancement and validation of the current geneType portfolio with a pipeline of publications in quality peer reviewed journals including:
Advancing the geneType Pipeline
GTG regards adding new expanded risk assessment tests to the company’s portfolio as a critical step in improving patient care. Leveraging this approach GTG is expanding the portfolio with the following new tests:
GTG’s CEO, Simon Morriss noted, “All of these important future initiatives highlight GTG’s ongoing commitment to continuous product improvement and new product development, underpinned by solid scientific validation and clinical utility. All the company’s risk assessment tests address areas of significant unmet medical need by assisting in stratifying people at elevated risk of disease and continuing to drive further adoption into the rapidly expanding area personalised medicine.”
Approved for release by the Chair of Board of Directors.
Enquiries
Investor Relations
Adrian Mulcahy
Automic Markets
M: +61 438 630 411
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness, and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com
Last Trade: | US$2.22 |
Daily Change: | 0.04 1.88 |
Daily Volume: | 20,208 |
Market Cap: | US$8.550M |
March 25, 2024 October 18, 2023 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB